North China Pharmaceutical's (SHA:600812) eight products won preliminary bids under China's drug procurement program, according to a Tuesday disclosure to the Shanghai Stock Exchange.
Two of the drugs, cyclosporine and tacrolimus capsules, are indicated for transplant patients, while edoxaban tosilate is an anticoagulant.
The other five products, teicoplanin, vancomycin hydrochloride, isavuconazonium sulfate, ceftazidime and avibactam sodium, and imipenem and cilastatin sodium, are all antibiotic injections.